There are accumulating evidences showing that targeting distinct multiple inhibitory epitopes on the IGF-1R and using a combination of competitive and allosteric antibodies may be more effective ways of affecting the IGF- 1R pathway in cancer [7, 29]. Here, IGF1R is linked to cancer.